Compare Cytokinetics Inc (CYTK) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Valero Energy Corporation — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Valero Energy Corporation trades at $300.02 (market cap $89.50B). The key difference: Valero Energy Corporation is far larger — about 8× Cytokinetics Inc's market cap, and Valero Energy Corporation pays a 1.59% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VLO | |
|---|---|---|
Market Cap | $11.12B | $89.50B |
Sector | Technology | Energy |
52-Week High | $87.26 | $301.43 |
52-Week Low | $33.23 | $131.77 |
Enterprise Value | $11.59B | $95.26B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Valero Energy (VLO) trades at $295.79, up 5.38% in the last session, reflecting strong momentum amid bullish technical signals and positive earnings surprises. The stock's valuation metrics, including a P/E of 20.5 and P/S of 0.69, appear reasonable relative to historical levels, while profitability remains solid with a 17.72% ROE. Recent news highlights VLO's exposure to elevated refining margins and strong fuel demand, particularly benefiting its Gulf Coast operations.
The outlook for VLO is supported by robust refining fundamentals and a favorable analyst consensus, though risks include volatile energy markets and declining revenue trends. Upside potential exists if the company continues to exceed earnings expectations and capitalizes on tight product supplies, but investors should monitor margin pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
